Ainos IncNASDAQ:AIMD
- LAST PRICE1.0401
- TODAY'S CHANGE (%)0.0001 (0.0096%)
- Bid / Lots1.0300/ 47
- Ask / Lots1.0700/ 1
- Open / Previous Close1.0400 / 1.0400
- Day Range
- 52 Week Range
- Volume6,722
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AIMD |
|---|---|---|
| 09:32 ET | 200 | 1.0301 |
| 09:36 ET | 100 | 1.04 |
| 10:12 ET | 100 | 1.04 |
| 11:13 ET | 100 | 1.04 |
| 11:18 ET | 225 | 1.03 |
| 11:40 ET | 300 | 1.04 |
| 12:07 ET | 400 | 1.0499 |
| 01:19 ET | 322 | 1.05 |
| 01:33 ET | 200 | 1.0499 |
| 01:35 ET | 100 | 1.03 |
| 02:15 ET | 100 | 1.04 |
| 02:27 ET | 1000 | 1.042 |
| 02:33 ET | 100 | 1.03 |
| 03:43 ET | 100 | 1.0401 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ainos Inc | 6.2M | -0.3x | --- |
Kazia Therapeutics Ltd | 9.8M | -0.5x | --- |
TC BioPharm Ltd | 5.0M | 0.0x | --- |
Kintara Therapeutics Inc | 6.2M | 0.0x | --- |
CeCors Inc | 6.2M | 0.0x | --- |
Mymd Pharmaceuticals Inc | 6.1M | -0.5x | --- |
Company Information
Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
Contact Information
- Headquarters
- 8880 Rio San Diego Drive, Ste. 800SAN DIEGO, CA, United States 92108
- Phone
- 858-869-2986
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer
- Chun-Hsien Tsai
- Chief Financial Officer
- Hsin-Liang Lee
- Executive Vice President - Operations
- Lawrence Lin
- Director
- Ting-Chuan Lee
- Director
- Chun-Jung Tsai
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.2M |
|---|---|
Revenue (TTM) | $122.1K |
Shares Outstanding | 6.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.47 |
EPS | $-3.32 |
Book Value | $5.23 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 50.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -10,738.02% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
